Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: <scp>A</scp> retrospective cohort study

Holden, Sarah E.; Morgan, Christopher L.; Qiao, Qing; Jenkins‐Jones, Sara; Berni, Ellen; Currie, Craig John

doi:10.1111/dom.12916

Cited by 3 publications

(9 citation statements)

References 25 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published study conducted in the UK also compared utilization and costs between patients with T2D initiating EQW and patients initiating BI, using primary care and inpatient data and unit costs for other sources. 15 Consistent with our study, EQW initiators had significantly higher costs for glucose-lowering therapies than BI initiators (926 GBP per patient-year vs 556 GBP per patient-year). 15 Costs for primary care visits (944 GBP vs 1059 GBP) and hospital admissions (654 GBP vs 1349 GBP) were significantly lower for patients initiating EQW.…”

Section: Discussionsupporting

confidence: 89%

“…15 Consistent with our study, EQW initiators had significantly higher costs for glucose-lowering therapies than BI initiators (926 GBP per patient-year vs 556 GBP per patient-year). 15 Costs for primary care visits (944 GBP vs 1059 GBP) and hospital admissions (654 GBP vs 1349 GBP) were significantly lower for patients initiating EQW. 15 Overall, total costs per patient-year in the UK were significantly lower for EQW initiators compared with BI initiators (2646 GBP vs 3283 GBP).…”

Section: Discussionsupporting

confidence: 89%

“…The findings are consistent with other published analyses comparing EQW and exenatide twice daily (EBID) with insulin. A recently published study conducted in the UK also compared utilization and costs between patients with T2D initiating EQW and patients initiating BI, using primary care and inpatient data and unit costs for other sources . Consistent with our study, EQW initiators had significantly higher costs for glucose‐lowering therapies than BI initiators (926 GBP per patient‐year vs 556 GBP per patient‐year) .…”

Section: Discussionsupporting

confidence: 84%

“…The UK‐based study also compared EBID with BI and found similar results, with EBID patients having significantly higher costs for glucose‐lowering therapies (834 GBP vs 556 GBP), but lower total costs (2532 GBP vs 3070 GBP) . Several claims‐based studies in the USA have also compared EBID with IG.…”

Section: Discussionmentioning

confidence: 85%

“…To date, only 1 other published analysis has compared costs between patients treated with EQW and BI. That study was conducted in the UK, and the authors reported that EQW use was associated with lower costs overall, despite higher costs for glucose‐lowering therapies . Therefore, the objective of this real‐world, claims‐based analysis was to compare all‐cause and diabetes‐related healthcare utilization and costs between adults with T2D initiating EQW and those initiating IG in the USA.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

Wittbrodt

Kong

Moore‐Schiltz

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

Wittbrodt

Kong

Moore‐Schiltz

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study

et al. 2018

Self Cite

View full text Add to dashboard Cite

IntroductionThe aim of the study was to compare glycemic and weight change outcomes for type 2 diabetes patients treated with either exenatide once-weekly (EQW) or exenatide twice-daily (EBID) with those patients treated with basal insulin (BI).MethodsRetrospective data (2010–2014) were extracted from the Clinical Practice Research Datalink, a UK primary care database. Patients previously naïve to injectable therapy initiating EQW, EBID, or BI were extracted and matched by propensity score within two analyses (EQW vs BI and EBID vs BI). Absolute and relative change in HbA1c and weight from baseline and the proportion of patients achieving HbA1c ≤ 7.0% (53 mmol/mol) combined with weight reduction targets of (1) any weight loss or (2) ≥ 5.0% from baseline were compared at 6 and 12–24 months.ResultsA total of 485 patients initiated EQW, 3573 EBID, and 13,503 BI. In the propensity matched EQW versus BI analysis, mean HbA1c decreased with changes of − 1.33% (− 14.5 mmol/mol) and − 1.24% (− 13.5 mmol/mol) at 6 months and − 1.19% (− 13.0 mmol/mol) and − 1.17% (− 12.8 mmol/mol) at 12–24 months, respectively. Respective weight change was − 3.7 kg versus + 1.2 kg (p < 0.001) and − 3.2 kg versus + 2.5 kg (p < 0.001). Significantly more EQW patients achieved the combined HbA1c ≤ 7.0% (53 mmol/mol) and weight loss target (22.4% versus 9.9% at 6 months and 18.2% versus 8.0% at 12–24 months, respectively) and HbA1c ≤ 7.0% (53 mmol/mol) and minimum 5% weight loss (11.8% versus 3.7% at 6 months, and 8.0% versus 0.0% at 12–24 months). For EBID versus BI, similar results were found.ConclusionIn this real-world data analysis, exenatide QW and exenatide BID were associated with similar glycemic control and greater weight reduction compared with basal insulin.

show abstract

Rising Incidence, Health Resource Utilization, and Costs of Polycystic Ovary Syndrome in the United Kingdom

Berni,

Morgan,

Rees

2024

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Trends in incidence of Polycystic Ovary Syndrome (PCOS) and effects on health resource utilization are unclear. Objectives To describe trends in prevalence and incidence of PCOS in the United Kingdom. To establish healthcare resource use and associated costs. Design Data were extracted from the Clinical Practice Research Datalink Aurum and Hospital Episode Statistics databases. Point prevalence and incidence were calculated (2004-2020). Patients with PCOS were matched to controls (1:1) by age, body mass index and primary care practice. Primary care contacts were assigned an average cost and prescription items assigned a net ingredient cost. Inpatient admissions and outpatient consultations were processed into Healthcare Resource Groups and costed to the National Tariff. Results PCOS incidence increased from 1.22 per 1000 person years in 2004 to 1.77 (2012) and 2.20 (2019). Point prevalence increased from 1.02% (2004) to 2.2% (2012) and 3.5% (2020), and was highest in Asians. Mean contacts per person year (ppy) for patients with PCOS versus controls were 0.48 vs 0.29 for inpatients (p<0.001), 3.81 vs 2.15 for outpatients (p<0.001) and 6.43 vs 4.68 (p<0.001) for primary care. Mean healthcare costs (ppy) were £837 vs £493 (p<0.001) for inpatients, £444 vs £253 (p<0.001) for outpatients, £157 vs £112 for primary care and £109 vs £83 (p<0.001) for primary care prescriptions. Total health care contacts ppy were 10.72 vs 7.11 (p<0.001) and total associated costs £1,546 vs £940 (p<0.001). Conclusion The incidence of PCOS has risen significantly. Health resource utilization and costs of PCOS are significantly greater than controls.

show abstract

Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study

Abstract: Overall, exenatide once-weekly and twice-daily-based regimens were associated with reduced healthcare resource use and costs compared with basal-insulin-based regimens.

Cited by 3 publications

References 25 publications

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study

Rising Incidence, Health Resource Utilization, and Costs of Polycystic Ovary Syndrome in the United Kingdom

Contact Info

Product

Resources

About